Published on: Aug 25, 2016 at Targeted Oncology

Apatinib Shows Promising Survival Advantage in Advanced Gastric Cancer

By : Targeted Oncology

Apatinib demonstrated an improvement in overall survival (OS) by 1.8 months and an acceptable toxicity profile compared to placebo as treatment for advanced gastric cancer, according to findings published in the Journal of Clinical Oncology

Read More
SHARE